National R&D expenditure
Reported by the National Bureau of Statistics for 2024, including RMB 250.09 billion in basic research.
Source: China’s 2024 national science and technology expenditure communiqué
OrientSciences research context
Why China matters
in biotechnology research.
China’s research investment, medical product innovation and clinical infrastructure make it an important centre for biotechnology research. OrientSciences treats this as context, not as evidence for any individual product.
Research scale, peptide innovation and documented evidence. The scale in numbersChina’s research
China’s research
capacity.
These facts, with links to their sources, describe the scale of China’s research environment. They make no claims about the safety, efficacy, status or quality of any OrientSciences product.
First-in-class innovative drugs
Reported by China’s NMPA as approved in 2024. This indicates the scale of the research environment, not the quality of any product.
Source: NMPA report on first-in-class innovative-drug approvalsTrial records in China
Identified in a 2023 peer-reviewed analysis of Chinese Clinical Trial Registry records through October 2020.
Source: Chinese Clinical Trial Registry 13-year data collection and analysis The OrientSciences approachScale provides context.
Scale provides context.
Evidence relates to each product.
OrientSciences should present this context without overstating what it shows. Every catalogue record must be assessed independently of the national research story.
Scale provides context
OECD data show China’s R&D expenditure reached 96% of the United States’ level in 2023 when measured in PPP-adjusted dollars.
Read the OECD R&D analysisBiopharma innovation has expanded
CSIS reports that China’s share of the global biopharmaceutical innovation pipeline rose from 4.1% in 2015 to 13.9% in 2020.
Read the CSIS biopharma analysis Explore the catalogueExplore the OrientSciences
Browse all research records